Identification

Name
Diphenoxylate
Accession Number
DB01081  (APRD00366)
Type
Small Molecule
Groups
Approved, Illicit
Description

A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.

Structure
Thumb
Synonyms
  • 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester
  • 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile
  • 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile
  • Difenossilato
  • Difenoxilato
  • Diphenoxylatum
  • Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate
  • Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate
External IDs
DEA No. 9170 / IDS-ND-016 / R-1132
Product Ingredients
IngredientUNIICASInChI Key
Diphenoxylate HydrochlorideW24OD7YW483810-80-8SHTAFWKOISOCBI-UHFFFAOYSA-N
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Diphenoxylate Hcl and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralStat Rx USA1979-10-29Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralAvera Mc Kennan Hospital2015-04-06Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralUnit Dose Services2013-02-27Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralA S Medication Solutions1977-11-17Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralKaiser Foundations Hospitals2010-11-30Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralCardinal Health2010-11-302016-02-25Us
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralDirectrx2015-01-01Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralAtlantic Biologicals Corps.2013-02-27Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralPhysicians Total Care, Inc.1995-01-27Not applicableUs
Diphenoxylate Hydrochloride and Atropine SulfateDiphenoxylate Hydrochloride (2.5 mg/1) + Atropine Sulfate (.025 mg/1)TabletOralDispensing Solutions, Inc.2010-11-30Not applicableUs
Categories
UNII
73312P173G
CAS number
915-30-0
Weight
Average: 452.5873
Monoisotopic: 452.246378278
Chemical Formula
C30H32N2O2
InChI Key
HYPPXZBJBPSRLK-UHFFFAOYSA-N
InChI
InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
IUPAC Name
ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
SMILES
CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1

Pharmacology

Indication

For as adjunctive therapy in the management of diarrhea

Structured Indications
Pharmacodynamics

Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.

Mechanism of action

Diphenoxylate is an opiate receptor agonists that stimulate mu receptors in GI to decrease the peristalsis and constrict the sphincters. Diphenoxylate has a direct effect on circular smooth muscle of the bowel, that conceivably results in segmentation and prolongation of gastrointestinal transit time. The clinical antidiarrheal action of diphenoxylate may thus be a consequence of enhanced segmentation that allows increased contact of the intraluminal contents with the intestinal mucosa.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
UDelta-type opioid receptor
agonist
Human
Absorption

90%

Volume of distribution
Not Available
Protein binding

74-95%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

12-14 hours

Clearance
Not Available
Toxicity

Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Diphenoxylate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Diphenoxylate.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Diphenoxylate.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Diphenoxylate.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Diphenoxylate.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Agomelatine.Approved, Investigational
AlaproclateDiphenoxylate may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Diphenoxylate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Diphenoxylate.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Diphenoxylate.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenoxylate.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Diphenoxylate which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Diphenoxylate.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Asenapine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Diphenoxylate.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Diphenoxylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Diphenoxylate.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azaperone.Vet Approved
AzelastineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Diphenoxylate.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Diphenoxylate.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Diphenoxylate.Approved
BL-1020BL-1020 may increase the hypotensive activities of Diphenoxylate.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Diphenoxylate.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bupivacaine.Approved, Investigational
BuprenorphineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenoxylate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenoxylate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diphenoxylate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Diphenoxylate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diphenoxylate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Diphenoxylate.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Diphenoxylate.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Diphenoxylate.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Diphenoxylate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cinchocaine.Approved, Vet Approved
CitalopramDiphenoxylate may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenoxylate.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Diphenoxylate.Approved
CocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Diphenoxylate.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Diphenoxylate.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dapiprazole.Approved
DapoxetineDiphenoxylate may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Diphenoxylate.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.Approved
DesvenlafaxineDiphenoxylate may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Diphenoxylate.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Diphenoxylate.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphenoxylate.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Drotebanol.Experimental, Illicit
DuloxetineDiphenoxylate may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efonidipine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eltanolone.Investigational
EluxadolineDiphenoxylate may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Diphenoxylate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Eplerenone.Approved
EscitalopramDiphenoxylate may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenoxylate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Diphenoxylate.Experimental
EthanolDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Diphenoxylate.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etomidate.Approved
EtoperidoneDiphenoxylate may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Diphenoxylate.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenoxylate.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Diphenoxylate.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunitrazepam.Approved, Illicit
FluoxetineDiphenoxylate may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diphenoxylate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diphenoxylate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenoxylate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenoxylate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Diphenoxylate.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Diphenoxylate.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepefrineGepefrine may increase the analgesic activities of Diphenoxylate.Experimental
GepironeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Diphenoxylate.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diphenoxylate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Diphenoxylate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Diphenoxylate.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Diphenoxylate.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Diphenoxylate.Approved
IbopamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Imipramine.Approved
IndalpineDiphenoxylate may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Diphenoxylate.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Diphenoxylate.Approved
IproclozideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Diphenoxylate.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levomethadyl Acetate.Approved
LevomilnacipranDiphenoxylate may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenoxylate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Diphenoxylate.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenoxylate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenoxylate.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Diphenoxylate.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Diphenoxylate.Approved
MeclizineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Diphenoxylate.Investigational
MephentermineMephentermine may increase the analgesic activities of Diphenoxylate.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Diphenoxylate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Diphenoxylate.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenoxylate.Approved
MethotrimeprazineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Diphenoxylate.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Diphenoxylate.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methylphenobarbital.Approved
MeticraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Diphenoxylate.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone.Approved
MetyrosineDiphenoxylate may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Diphenoxylate.Experimental, Illicit
MilnacipranDiphenoxylate may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Investigational
MirtazapineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Diphenoxylate.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Diphenoxylate.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Diphenoxylate.Approved
NaltrexoneThe therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneDiphenoxylate may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Opium.Approved, Illicit
OrphenadrineDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Diphenoxylate.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenoxylate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxethazaine.Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Diphenoxylate.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphenoxylate.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenoxylate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Diphenoxylate.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Diphenoxylate.Approved
ParaldehydeDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pargyline.Approved
ParoxetineDiphenoxylate may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenoxylate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenoxylate.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Diphenoxylate.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved
PerazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Diphenoxylate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Diphenoxylate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Diphenoxylate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Diphenoxylate.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Diphenoxylate.Approved
PiretanideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDiphenoxylate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diphenoxylate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenoxylate.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Diphenoxylate.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Diphenoxylate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Diphenoxylate.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Diphenoxylate.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Diphenoxylate.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenoxylate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Diphenoxylate is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Diphenoxylate.Approved
QuazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Diphenoxylate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ramelteon.Approved, Investigational
RamosetronDiphenoxylate may increase the constipating activities of Ramosetron.Approved
RasagilineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenoxylate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenoxylate.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenoxylate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Diphenoxylate.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Romifidine.Vet Approved
RopiniroleDiphenoxylate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ropivacaine.Approved
RotigotineDiphenoxylate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Diphenoxylate.Approved
SafrazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Diphenoxylate.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenoxylate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sertindole.Approved, Withdrawn
SertralineDiphenoxylate may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Diphenoxylate.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Diphenoxylate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sultopride.Experimental
SuvorexantDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenoxylate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrodotoxin.Investigational
ThalidomideDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Diphenoxylate.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Diphenoxylate.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diphenoxylate.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Diphenoxylate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Diphenoxylate.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Diphenoxylate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenoxylate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenoxylate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Diphenoxylate.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Diphenoxylate.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Diphenoxylate.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Diphenoxylate.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Diphenoxylate.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Diphenoxylate.Approved
UlaritideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Diphenoxylate.Approved
VenlafaxineDiphenoxylate may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenoxylate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ziconotide.Approved
ZimelidineDiphenoxylate may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zolazepam.Vet Approved
ZolpidemDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Janssen, P.A.J.; U.S.Patent 2,898,340; August 4,1959. Dryden, H.L. Jr. and Erickson, R.A.; U.S. Patent 4,086,234; April 25,1978; assigned to G.D.Searle & Co.

General References
Not Available
External Links
Human Metabolome Database
HMDB15213
KEGG Drug
D00301
KEGG Compound
C07872
PubChem Compound
13505
PubChem Substance
46507130
ChemSpider
12919
BindingDB
50401672
ChEBI
4639
ChEMBL
CHEMBL1201294
Therapeutic Targets Database
DAP001136
PharmGKB
PA164746539
RxList
RxList Drug Page
Wikipedia
Diphenoxylate
ATC Codes
A07DA01 — Diphenoxylate
AHFS Codes
  • 56:08.00 — Antidiarrhea Agents
MSDS
Download (49.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedDiagnosticMalignant Lymphomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionOral
TabletOral
Prices
Unit descriptionCostUnit
Lomotil 2.5-0.025 mg/5ml Liquid 60ml Bottle30.86USD bottle
Lomotil 2.5-0.025 mg tablet1.4USD tablet
Lomotil tablet1.12USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220.5-222Janssen, P.A.J.; U.S.Patent 2,898,340; August 4,1959. Dryden, H.L. Jr. and Erickson, R.A.; U.S. Patent 4,086,234; April 25,1978; assigned to G.D.Searle & Co.
water solubility800 mg/L (at 25 °C)MERCK INDEX (1996)
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00146 mg/mLALOGPS
logP5.74ALOGPS
logP5.88ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area53.33 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity146.76 m3·mol-1ChemAxon
Polarizability51.58 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9903
Blood Brain Barrier+0.9592
Caco-2 permeable+0.5316
P-glycoprotein substrateSubstrate0.7094
P-glycoprotein inhibitor IInhibitor0.7045
P-glycoprotein inhibitor IIInhibitor0.7845
Renal organic cation transporterInhibitor0.5967
CYP450 2C9 substrateNon-substrate0.8333
CYP450 2D6 substrateNon-substrate0.5667
CYP450 3A4 substrateNon-substrate0.5988
CYP450 1A2 substrateNon-inhibitor0.6827
CYP450 2C9 inhibitorInhibitor0.6701
CYP450 2D6 inhibitorInhibitor0.6461
CYP450 2C19 inhibitorInhibitor0.51
CYP450 3A4 inhibitorInhibitor0.5797
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.817
Ames testNon AMES toxic0.8482
CarcinogenicityNon-carcinogens0.839
BiodegradationNot ready biodegradable0.9805
Rat acute toxicity3.3423 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7969
hERG inhibition (predictor II)Inhibitor0.592
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0002-6591000000-e04da61bbde263b104e3
Mass Spectrum (Electron Ionization)MSsplash10-0002-2390000000-0d133bb29f340639db02
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0000900000-e2841fe11576faaa404e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0000900000-f16aa8a859221ed0173c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0220900000-38d21080081c6d144498
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0ap0-2920000000-ed4957b090e4b3a6f38d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aor-2900000000-becb90ead622a0131fdb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0210900000-f33819852c9168d0f8a0

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylacetonitriles
Direct Parent
Diphenylacetonitriles
Alternative Parents
Diphenylmethanes / Phenylpiperidines / Piperidinecarboxylic acids / Aralkylamines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Nitriles / Monocarboxylic acids and derivatives / Azacyclic compounds
show 4 more
Substituents
Diphenylacetonitrile / Diphenylmethane / Phenylpiperidine / Piperidinecarboxylic acid / Aralkylamine / Piperidine / Amino acid or derivatives / Carboxylic acid ester / Tertiary amine / Tertiary aliphatic amine
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, tertiary amine, nitrile, piperidinecarboxylate ester (CHEBI:4639)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Baker DE: Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. [PubMed:18192961]
  3. Corazziari E: Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol. 1999 Mar;13 Suppl A:71A-75A. [PubMed:10202212]
  4. Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6. [PubMed:8583364]
  5. De Luca A, Coupar IM: Difenoxin and loperamide: studies on possible mechanisms of intestinal antisecretory action. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):231-7. [PubMed:8386327]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Coupar IM: The peristaltic reflex in the rat ileum: evidence for functional mu- and delta-opiate receptors. J Pharm Pharmacol. 1995 Aug;47(8):643-6. [PubMed:8583364]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:28